OTCMKTS:BGMD - BG Medicine Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$0.04 0.00 (0.00 %)
(As of 05/22/2018 04:00 PM ET)
Previous Close$0.04
Today's Range$0.04 - $0.04
52-Week Range$0.02 - $0.09
Volume375 shs
Average Volume2,506 shs
Market Capitalization$450,000.00
P/E RatioN/A
Dividend YieldN/A

About BG Medicine (OTCMKTS:BGMD)

BG Medicine logoBG Medicine, Inc. engages in development and commercialization of diagnostic products used to guide the patients suffering from heart failure and related disorders in the United States. The company offers BGM Galectin-3 Test, an in vitro diagnostic device that measures galectin-3 in serum or plasma by enzyme linked immunosorbent assay on a microtiter plate platform; and CardioSCORE Test, a multi-analyte biomarker-based blood test used for the assessment of near-term risk of atherothrombotic cardiovascular events, such as heart attack and ischemic stroke. It has license, development, and commercialization agreements with Abbott Laboratories, bioMérieux SA, Siemens Healthcare Diagnostics Inc., and Alere Inc. for the automated instrument versions of galectin-3 test; and a strategic collaboration with Abbott Laboratories to develop and commercialize galectin-3 assay kits, and related control kits and calibrators. The company was formerly known as Beyond Genomics, Inc. and changed its name to BG Medicine, Inc. in October 2004. BG Medicine, Inc. was founded in 2000 and is headquartered in Waltham, Massachusetts.

Receive BGMD News and Ratings via Email

Sign-up to receive the latest news and ratings for BGMD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryLife Sciences Tools & Services


Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.57 million
Price / Sales0.29
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A


EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A


Outstanding Shares11,370,000

BG Medicine (OTCMKTS:BGMD) Frequently Asked Questions

What is BG Medicine's stock symbol?

BG Medicine trades on the OTCMKTS under the ticker symbol "BGMD."

How were BG Medicine's earnings last quarter?

BG Medicine (OTCMKTS:BGMD) released its earnings results on Tuesday, November, 17th. The medical research company reported ($0.27) earnings per share (EPS) for the quarter. The medical research company earned $334 million during the quarter, compared to analysts' expectations of $695 million. View BG Medicine's Earnings History.

Who are some of BG Medicine's key competitors?

Who are BG Medicine's key executives?

BG Medicine's management team includes the folowing people:
  • Dr. Paul R. Sohmer M.D., Chief Exec. Officer, Pres and Director (Age 69)
  • Mr. Stephen P. Hall, Chief Financial Officer, Exec. VP and Treasurer (Age 67)
  • Dr. Aram Adourian Ph.D., Chief Scientific Officer and Sr. VP (Age 48)
  • Dr. Noubar B. Afeyan Ph.D., Founder (Age 55)

Has BG Medicine been receiving favorable news coverage?

Headlines about BGMD stock have trended somewhat negative on Tuesday, according to Accern. Accern identifies positive and negative press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. BG Medicine earned a news impact score of -0.02 on Accern's scale. They also gave media stories about the medical research company an impact score of 47.23 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

How do I buy shares of BG Medicine?

Shares of BGMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BG Medicine's stock price today?

One share of BGMD stock can currently be purchased for approximately $0.04.

How big of a company is BG Medicine?

BG Medicine has a market capitalization of $450,000.00 and generates $1.57 million in revenue each year.

How can I contact BG Medicine?

BG Medicine's mailing address is 303 Wyman Street Suite 300, Waltham MA, 02451. The medical research company can be reached via phone at 781-890-1199 or via email at [email protected]

MarketBeat Community Rating for BG Medicine (BGMD)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  61 (Vote Outperform)
Underperform Votes:  52 (Vote Underperform)
Total Votes:  113
MarketBeat's community ratings are surveys of what our community members think about BG Medicine and other stocks. Vote "Outperform" if you believe BGMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BGMD will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

BG Medicine (OTCMKTS:BGMD) Analyst Ratings History

DateBrokerageActionRatingPrice TargetDetails
(Data available from 5/22/2016 forward)


BG Medicine (OTCMKTS:BGMD) Earnings History and Estimates Chart

Earnings by Quarter for BG Medicine (OTCMKTS:BGMD)

BG Medicine (OTCMKTS BGMD) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/4/2016Q4 2015($0.08)$0.29 millionViewN/AView Earnings Details
11/17/2015Q315($0.27)$695.00 million$334.00 millionViewN/AView Earnings Details
8/14/2015Q2($0.23)$0.51 millionViewListenView Earnings Details
5/14/2015Q115($0.03)($0.04)$1.60 million$0.44 millionViewListenView Earnings Details
3/31/2015Q414($0.05)($0.04)$0.55 millionViewN/AView Earnings Details
11/13/2014Q3 2014($0.28)$0.70 millionViewN/AView Earnings Details
8/14/2014Q214($0.06)($0.06)$1.40 million$2.20 millionViewN/AView Earnings Details
5/14/2014Q114($0.08)($0.08)$1.30 million$0.7390 millionViewN/AView Earnings Details
3/20/2014Q413($0.12)($0.06)$1.10 million$1.15 millionViewN/AView Earnings Details
11/6/2013Q3 2013($0.68)($0.52)$1.02 million$1.03 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.20)($0.18)$1.27 million$1.00 millionViewN/AView Earnings Details
5/9/2013Q1 2013($0.27)($0.21)$1.16 million$0.8880 millionViewN/AView Earnings Details
3/13/2013Q4 2012($1.28)($0.56)ViewN/AView Earnings Details
11/13/2012Q312($0.33)($0.34)ViewN/AView Earnings Details
8/9/2012Q2 2012($1.40)($1.28)ViewN/AView Earnings Details
5/15/2012Q1 2012($1.24)($1.54)ViewN/AView Earnings Details
3/8/2012Q4 2011($1.12)($0.92)ViewN/AView Earnings Details
11/3/2011Q3 2011($1.32)($1.01)ViewN/AView Earnings Details
8/11/2011Q2 2011($1.20)($1.01)ViewN/AView Earnings Details
5/12/2011Q1 2011($1.40)($1.07)ViewN/AView Earnings Details
3/16/2011Q4 2010($4.72)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)


BG Medicine (OTCMKTS:BGMD) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

BG Medicine (OTCMKTS BGMD) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 6.50%
Insider Trading History for BG Medicine (OTCMKTS:BGMD)

BG Medicine (OTCMKTS BGMD) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/9/2015Noubar AfeyanDirectorSell46,438$0.56$26,005.28View SEC Filing  
12/11/2014Edwin M Kania JrMajor ShareholderSell634,390$0.32$203,004.80View SEC Filing  
1/30/2013Stelios PapadopoulosDirectorBuy250,000$2.00$500,000.00View SEC Filing  
11/19/2012Brian S PosnerDirectorBuy10,000$1.17$11,700.00View SEC Filing  
11/15/2012Stephane BancelChairmanBuy100,000$1.26$126,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


BG Medicine (OTCMKTS BGMD) News Headlines

Analyzing Intellia Therapeutics (NTLA) & BG Medicine (BGMD)Analyzing Intellia Therapeutics (NTLA) & BG Medicine (BGMD)
www.americanbankingnews.com - May 11 at 1:15 PM
Myriad Genetics (MYGN) & BG Medicine (BGMD) Financial SurveyMyriad Genetics (MYGN) & BG Medicine (BGMD) Financial Survey
www.americanbankingnews.com - May 11 at 5:24 AM
Financial Contrast: BG Medicine (BGMD) versus Meridian Bioscience (VIVO)Financial Contrast: BG Medicine (BGMD) versus Meridian Bioscience (VIVO)
www.americanbankingnews.com - April 12 at 3:21 AM
BG Medicine (BGMD) versus Achieve Life Sciences (ACHV) Critical ComparisonBG Medicine (BGMD) versus Achieve Life Sciences (ACHV) Critical Comparison
www.americanbankingnews.com - April 6 at 5:14 PM
BG Medicine (BGMD) vs. Express Scripts (ESRX) Financial AnalysisBG Medicine (BGMD) vs. Express Scripts (ESRX) Financial Analysis
www.americanbankingnews.com - March 25 at 5:16 AM
Critical Analysis: BG Medicine (BGMD) vs. BioTelemetry (BEAT)Critical Analysis: BG Medicine (BGMD) vs. BioTelemetry (BEAT)
www.americanbankingnews.com - December 5 at 7:28 PM
Head to Head Analysis: BioTelemetry (BEAT) versus BG Medicine (BGMD)Head to Head Analysis: BioTelemetry (BEAT) versus BG Medicine (BGMD)
www.americanbankingnews.com - December 4 at 3:18 PM
Head-To-Head Analysis: BioTelemetry (BEAT) & BG Medicine (BGMD)Head-To-Head Analysis: BioTelemetry (BEAT) & BG Medicine (BGMD)
www.americanbankingnews.com - December 1 at 5:40 PM
Signal Genetics (MGEN) and BG Medicine (BGMD) Financial ContrastSignal Genetics (MGEN) and BG Medicine (BGMD) Financial Contrast
www.americanbankingnews.com - November 25 at 9:26 AM
BG Medicine (BGMD) and BioTelemetry (BEAT) Critical ComparisonBG Medicine (BGMD) and BioTelemetry (BEAT) Critical Comparison
www.americanbankingnews.com - November 17 at 9:30 PM

SEC Filings

BG Medicine (OTCMKTS:BGMD) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media


BG Medicine (OTCMKTS:BGMD) Income Statement, Balance Sheet and Cash Flow Statement


BG Medicine (OTCMKTS BGMD) Stock Chart for Tuesday, May, 22, 2018

Loading chart…

This page was last updated on 5/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.